Chemotherapy‐induced peripheral neurotoxicity: A critical analysis

Park, Susanna B.; Goldstein, David; Krishnan, Arun V.; Lin, Cindy S.‐Y.; Friedlander, Michael; Cassidy, James T.; Koltzenburg, M; Kiernan, Matthew C.

doi:10.3322/caac.21204

Cited by 576 publications

(581 citation statements)

References 230 publications

(428 reference statements)

Supporting

Mentioning

559

Contrasting

Unclassified

Order By: Relevance

“…[8] A higher incidence of paclitaxel neuropathy has been reported when paclitaxel is infused over three hours as compared to 24 hours. [11] We observed decreased incidence of neuropathy in the limbs treated with ice gloves and boots compared to controls during and post treatment with paclitaxel.…”

Section: Discusssionmentioning

confidence: 99%

“…Most patients will have improvement of symptoms over months to years post treatment with a small number developing chronic, treatment resistant neuropathy. [8,9] There are no published reports on cold therapy as preventive strategy for chemotherapy induced peripheral neuropathy. Anecdotal reports by patients of improvement or disappearance of peripheral neuropathy symptoms with the use of cold therapy used to prevent nail changes with docetaxel, generated the hypothesis for this study.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The impact of cold therapy on the incidence and severity of paclitaxel induced peripheral neuropathy: A pilot study

Younus¹,

Kligman²,

Jawaid

2016

JST

View full text Add to dashboard Cite

Background: Peripheral neuropathy is a common side effect induced by chemotherapy agents like Cisplatin, Paclitaxel and Docetaxel. At present, there is no preventive strategy available against the development of neuropathy. This pilot study was performed to evaluate the feasibility of cold therapy and its impact on the incidence and severity of neuropathy induced by paclitaxel in a dose dense adjuvant regimen among patients with breast cancer. Methods: All adult female patients with early breast cancer planned to be treated with dose-dense schedule of Adriamycin, cyclophosphamide and Paclitaxel were eligible. Ice boot and glove were applied for the duration of all four Paclitaxel infusions on one side while the contralateral limbs were taken as control. Peripheral neuropathy was evaluated and graded prior to each Paclitaxel infusion and then at 3 and 6 months post treatment. Results: A total of 23 patients were recruited. Cold therapy was found to be feasible as no patient discontinued the ice glove and boot during Paclitaxel infusions. Neuropathy symptoms were observed more frequently and with higher grade of severity on control limbs compared to experimental side. There were 5 patients who were switched to ice glove and boot therapy after they developed peripheral neuropathy in the control limbs. These patients observed improvement in their symptoms subsequently. Conclusion: Cold therapy appears to be feasible and appears to have some potential to prevent Paclitaxel induced peripheral neuropathy in this pilot study. This role of cold therapy may be further explored and confirmed in future randomized trials.

show abstract

Section: Discusssionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The impact of cold therapy on the incidence and severity of paclitaxel induced peripheral neuropathy: A pilot study

Younus¹,

Kligman²,

Jawaid

2016

JST

View full text Add to dashboard Cite

show abstract

“…Although cisplatin is one of the most remarkable anticancer drugs, its use is limited by severe side effects in normal tissues including neurotoxicity and nephrotoxicity, with an incidence of approximately 33% (Ries and Klastersky, 1986;Park et al, 2013). Several renoprotective approaches have been introduced such as inhibition of cisplatin uptake (Ciarimboli et al, 2005), inhibition of oxidative stress (Gao et al, 2013), and modulation of cell death pathways (Park et al, 2002).…”

Section: Discussionmentioning

confidence: 99%

“…The therapeutic effects are dose-dependent; however, high dose cisplatin is limited by cumulative nephrotoxicity (Pabla and Dong, 2008) and neurotoxicity (Park et al, 2013). Cisplatin primarily targets renal proximal tubular cells, inducing renal tubular cell damage and promoting nephrotoxicity through several mechanisms including oxidative stress, DNA damage, and inflammation (Clark et al, 2010;Pabla and Dong, 2008).…”

Section: Introductionmentioning

confidence: 99%

Fenofibrate reduces cisplatin-induced apoptosis of renal proximal tubular cells via inhibition of JNK and p38 pathways

et al. 2016

View full text Add to dashboard Cite

-Cisplatin is widely used as a standard chemotherapy for solid tumors. The major adverse effect of cisplatin is nephrotoxicity in proximal tubular cells, via oxidative stress, DNA damage, cell apoptosis, and inflammation. The aim of this study was to investigate the pharmacological effect and mechanism of fibrate drugs on cisplatin-induced renal proximal tubular cell death. Cisplatin decreased cell viability of LLC-PK1 and HK-2 cells in a dose-dependent manner. Cisplatin-induced apoptosis was attenuated by co-treatment with fenofibrate while less so with clofibrate and bezafibrate. Fenofibrate's protective effect was not complimented by co-treatment with GW6471, a PPARα antagonist, indicating the protective effect occurred via a PPARα-independent mechanism. Treating cells with cisplatin induced reactive oxygen species (ROS), c-JUN N-terminal kinase (JNK), and p38 kinase (p38), but not extracellular signal-regulated kinase (ERK). Fenofibrate reversed cisplatin-induced JNK and p38 activation, but had no effect on ROS production. The findings suggest fenofibrate's protective effect on cisplatin-induced cytotoxicity is mediated by inhibition of JNK and p38. Moreover, fenofibrate did not alter cisplatin's antitumor effect on cancer cell lines including T84, SW-480, HepG2, and SK-LU-1 cells. Therefore, fenofibrate may be a candidate agent for further development as an adjuvant to cisplatin treatment.

show abstract

“…51 The incidence of thalidomide-induced PNP (TiPNP) is dependent on dose, treatment duration, and patient specific factors, and presents as a sensory neuropathy with prominent symptoms of paresthesia in the hands and feet (glove-and-stocking distribution). 49,52,53 TiPNP also includes numbness, and mild motor involvement with muscle cramps and weakness. 53 (Table 3).…”

Section: Peripheral Neuropathymentioning

confidence: 99%

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network

Ludwig

Delforge²,

Facon

et al. 2017

Leukemia

View full text Add to dashboard Cite

During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drugs classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.

show abstract

Chemotherapy‐induced peripheral neurotoxicity: A critical analysis

Cited by 576 publications

References 230 publications

The impact of cold therapy on the incidence and severity of paclitaxel induced peripheral neuropathy: A pilot study

The impact of cold therapy on the incidence and severity of paclitaxel induced peripheral neuropathy: A pilot study

Fenofibrate reduces cisplatin-induced apoptosis of renal proximal tubular cells via inhibition of JNK and p38 pathways

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network

Contact Info

Product

Resources

About